Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 13OTHER 10NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Lung Neoplasms 2Neoplasms 1Neoplasm Metastasis 1Metastatic Pancreatic Adenocarcinoma 1Mesothelioma 1Breast Neoplasms 1

Interventions

Carboplatin 41Cisplatin 38Paclitaxel 34Specimen Handling 32Radiotherapy 27Magnetic Resonance Spectroscopy 25Gemcitabine 23Vinorelbine 15Etoposide 15Docetaxel 15Biopsy 13Pemetrexed 10Cyclophosphamide 10pembrolizumab 9Taxes 9Immunoglobulin G 9Disulfides 9Platinum 81,2-diaminocyclohexaneplatinum II citrate 8X-Rays 7Vinblastine 7Erlotinib Hydrochloride 7osimertinib 6durvalumab 6atezolizumab 6Nivolumab 6Irinotecan 6Ifosfamide 6Chemotherapy, Adjuvant 6Celecoxib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Lung Neoplasms × 130-nm albumin-bound paclitaxel × Clear all
NCT06096844 2026-06-03

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

National Cancer Institute (NCI)

Phase 3 Recruiting
304 enrolled
Thoracic

Lung Neoplasms

NCT04310007 2026-05-29

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
117 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡